-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Trevi Therapeutics, Lowers Price Target to $24

Benzinga·03/19/2025 11:39:27
Listen to the news
Needham analyst Serge Belanger maintains Trevi Therapeutics (NASDAQ:TRVI) with a Buy and lowers the price target from $25 to $24.